 The FDA has placed a partial clinical hold on Alpine Immune Sciences Incs NASDAQ: ALPN NEON-2 trial evaluating davoceticept ALPN-202 in combination with pembrolizumab in adults with advanced malignancies. The partial clinical hold was prompted by Alpines report of. 